EMEA-002124-PIP01-17
Key facts
Active substance |
Pexastimogene devacirepvec
|
Therapeutic area |
Oncology
|
Decision number |
P/0201/2017
|
PIP number |
EMEA-002124-PIP01-17
|
Pharmaceutical form(s) |
Suspension for injection
|
Condition(s) / indication(s) |
Treatment of hepatocellular carcinoma
|
Route(s) of administration |
Intratumoral use
|
Contact for public enquiries |
Transgene S.A.
|
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|